Profil News

Our expert

Dr. Lars Bochmann

Executive Director Commercial Operations

November 14, 2024

Downtime Impact Factor evaluates downtime in automated glucose clamps

The euglycemic hyperinsulinemic glucose clamp technique is the gold standard for the determination of pharmacokinetic (PK) and pharmacodynamic (PD) effects of (new) glucose lowering drugs, insulins

September 30, 2024

AI in Clinical Research: Transforming the Future of Medicine

Artificial Intelligence (AI) has rapidly become a transformative force across numerous industries, and clinical research is no exception. The integration of AI into clinical research is

September 10, 2024

Live Online Seminar: MASH Pharmacotherapy - On the Brink of a New Era

We are happy to announce that our successful series of scientific online seminars continues. On October 08th, 2024 at 4:00PM CEST we will air our next complimentary live online seminar. The session

August 27, 2024

A Seven-Step Guide to Navigating New EU Regulations for Medical Devices

The regulatory landscape for medical device manufacturers in the EU has changed significantly with the introduction of new regulations. Navigating these requirements can be challenging, but with the

July 31, 2024

The German Medical Research Act: Transforming Clinical Trials

Germany is on the brink of a pivotal transformation in the pharmaceutical research landscape with the upcoming Medical Research Act. This legislative milestone is part of the government's broader

July 4, 2024

Live Online Seminar: Initiative Germany as a Location for Clinical Trials

We are happy to announce that our successful series of scientific online seminars continues. On July 30th, 2024 at 6 PM CEST we will air our next complimentary live online seminar. The session is

May 29, 2024

Accelerating Innovation: The Impact of CROs on European Biotech SMEs

In the constantly evolving landscape of the biotech industry, small and medium-sized enterprises (SMEs) in Europe are finding an invaluable ally in Contract Research Organizations (CROs). Among

April 30, 2024

Navigating Financial Incentives for SMEs in Europe's Biotech Landscape

In the challenging yet promising field of biotechnology, particularly within the domains of obesity and diabetes research, the journey from concept to commercial success is intricate and

March 26, 2024

First drug approved for NASH

On March 14, 2024, Madrigal Pharmaceuticals received the first regulatory approval for a drug targeting NonAlcoholic SteatoHepatitis (NASH). Specifically, FDA approved Rezdiffra (resmetirom) for the